vs

Side-by-side financial comparison of ASHFORD HOSPITALITY TRUST INC (AHT) and BIOCRYST PHARMACEUTICALS INC (BCRX). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($406.6M vs $259.0M, roughly 1.6× ASHFORD HOSPITALITY TRUST INC). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs -26.8%, a 87.2% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs -6.0%). BIOCRYST PHARMACEUTICALS INC produced more free cash flow last quarter ($291.2M vs $-86.8M). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs -7.7%).

Ashford Hospitality Trust Inc is a U.S.-headquartered real estate investment trust focused on upper-upscale full-service hotel properties across key U.S. urban, suburban and resort markets. Its portfolio holds assets under top global hospitality brands, serving business and leisure travelers, with a focus on long-term value growth and stable shareholder returns.

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

AHT vs BCRX — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.6× larger
BCRX
$406.6M
$259.0M
AHT
Growing faster (revenue YoY)
BCRX
BCRX
+215.1% gap
BCRX
209.1%
-6.0%
AHT
Higher net margin
BCRX
BCRX
87.2% more per $
BCRX
60.5%
-26.8%
AHT
More free cash flow
BCRX
BCRX
$378.0M more FCF
BCRX
$291.2M
$-86.8M
AHT
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
-7.7%
AHT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AHT
AHT
BCRX
BCRX
Revenue
$259.0M
$406.6M
Net Profit
$-69.3M
$245.8M
Gross Margin
97.7%
Operating Margin
-2.6%
64.0%
Net Margin
-26.8%
60.5%
Revenue YoY
-6.0%
209.1%
Net Profit YoY
44.2%
1017.5%
EPS (diluted)
$-12.85
$1.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AHT
AHT
BCRX
BCRX
Q4 25
$259.0M
$406.6M
Q3 25
$266.1M
$159.4M
Q2 25
$302.0M
$163.4M
Q1 25
$277.4M
$145.5M
Q4 24
$275.5M
$131.5M
Q3 24
$276.6M
$117.1M
Q2 24
$316.5M
$109.3M
Q1 24
$303.9M
$92.8M
Net Profit
AHT
AHT
BCRX
BCRX
Q4 25
$-69.3M
$245.8M
Q3 25
$-60.1M
$12.9M
Q2 25
$-30.4M
$5.1M
Q1 25
$-20.0M
$32.0K
Q4 24
$-124.2M
$-26.8M
Q3 24
$-57.9M
$-14.0M
Q2 24
$50.3M
$-12.7M
Q1 24
$71.6M
$-35.4M
Gross Margin
AHT
AHT
BCRX
BCRX
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Q1 24
98.6%
Operating Margin
AHT
AHT
BCRX
BCRX
Q4 25
-2.6%
64.0%
Q3 25
4.6%
18.6%
Q2 25
16.3%
18.2%
Q1 25
22.2%
14.6%
Q4 24
-17.8%
-3.4%
Q3 24
7.3%
6.6%
Q2 24
42.8%
8.0%
Q1 24
50.2%
-15.6%
Net Margin
AHT
AHT
BCRX
BCRX
Q4 25
-26.8%
60.5%
Q3 25
-22.6%
8.1%
Q2 25
-10.1%
3.1%
Q1 25
-7.2%
0.0%
Q4 24
-45.1%
-20.4%
Q3 24
-20.9%
-12.0%
Q2 24
15.9%
-11.6%
Q1 24
23.5%
-38.1%
EPS (diluted)
AHT
AHT
BCRX
BCRX
Q4 25
$-12.85
$1.13
Q3 25
$-11.35
$0.06
Q2 25
$-6.88
$0.02
Q1 25
$-4.91
$0.00
Q4 24
$-13.64
$-0.13
Q3 24
$-12.39
$-0.07
Q2 24
$2.50
$-0.06
Q1 24
$5.99
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AHT
AHT
BCRX
BCRX
Cash + ST InvestmentsLiquidity on hand
$66.1M
$274.7M
Total DebtLower is stronger
$2.5B
Stockholders' EquityBook value
$-626.4M
$-119.2M
Total Assets
$2.8B
$514.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AHT
AHT
BCRX
BCRX
Q4 25
$66.1M
$274.7M
Q3 25
$81.9M
$212.9M
Q2 25
$100.0M
$260.0M
Q1 25
$85.8M
$295.1M
Q4 24
$112.9M
$320.9M
Q3 24
$119.7M
$96.8M
Q2 24
$121.8M
$78.4M
Q1 24
$111.1M
$84.3M
Total Debt
AHT
AHT
BCRX
BCRX
Q4 25
$2.5B
Q3 25
$2.6B
Q2 25
$2.6B
Q1 25
$2.7B
Q4 24
$2.6B
Q3 24
$2.7B
Q2 24
$2.8B
Q1 24
$2.9B
Stockholders' Equity
AHT
AHT
BCRX
BCRX
Q4 25
$-626.4M
$-119.2M
Q3 25
$-548.7M
$-387.9M
Q2 25
$-485.5M
$-421.6M
Q1 25
$-446.1M
$-451.9M
Q4 24
$-419.2M
$-475.9M
Q3 24
$-288.4M
$-468.6M
Q2 24
$-225.9M
$-475.6M
Q1 24
$-276.8M
$-476.2M
Total Assets
AHT
AHT
BCRX
BCRX
Q4 25
$2.8B
$514.2M
Q3 25
$3.0B
$446.4M
Q2 25
$3.1B
$457.2M
Q1 25
$3.1B
$480.0M
Q4 24
$3.2B
$490.4M
Q3 24
$3.3B
$491.3M
Q2 24
$3.3B
$472.4M
Q1 24
$3.5B
$467.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AHT
AHT
BCRX
BCRX
Operating Cash FlowLast quarter
$-15.7M
$292.0M
Free Cash FlowOCF − Capex
$-86.8M
$291.2M
FCF MarginFCF / Revenue
-33.5%
71.6%
Capex IntensityCapex / Revenue
27.5%
0.2%
Cash ConversionOCF / Net Profit
1.19×
TTM Free Cash FlowTrailing 4 quarters
$-135.5M
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AHT
AHT
BCRX
BCRX
Q4 25
$-15.7M
$292.0M
Q3 25
$5.5M
$41.6M
Q2 25
$16.3M
$41.3M
Q1 25
$-25.0M
$-27.5M
Q4 24
$-23.6M
$-5.2M
Q3 24
$795.0K
$8.2M
Q2 24
$8.0M
$-1.4M
Q1 24
$-46.5M
$-53.7M
Free Cash Flow
AHT
AHT
BCRX
BCRX
Q4 25
$-86.8M
$291.2M
Q3 25
$-226.0K
$40.3M
Q2 25
$-3.6M
$41.1M
Q1 25
$-44.8M
$-27.7M
Q4 24
$-131.6M
$-5.9M
Q3 24
$-21.8M
$8.2M
Q2 24
$-22.9M
$-1.5M
Q1 24
$-80.4M
$-53.9M
FCF Margin
AHT
AHT
BCRX
BCRX
Q4 25
-33.5%
71.6%
Q3 25
-0.1%
25.3%
Q2 25
-1.2%
25.2%
Q1 25
-16.2%
-19.0%
Q4 24
-47.8%
-4.5%
Q3 24
-7.9%
7.0%
Q2 24
-7.2%
-1.4%
Q1 24
-26.5%
-58.1%
Capex Intensity
AHT
AHT
BCRX
BCRX
Q4 25
27.5%
0.2%
Q3 25
2.1%
0.8%
Q2 25
6.6%
0.1%
Q1 25
7.2%
0.1%
Q4 24
39.2%
0.5%
Q3 24
8.2%
0.1%
Q2 24
9.8%
0.1%
Q1 24
11.2%
0.3%
Cash Conversion
AHT
AHT
BCRX
BCRX
Q4 25
1.19×
Q3 25
3.23×
Q2 25
8.12×
Q1 25
-859.91×
Q4 24
Q3 24
Q2 24
0.16×
Q1 24
-0.65×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AHT
AHT

Occupancy$190.2M73%
Food And Beverage$51.8M20%
Hotel Other$16.6M6%

BCRX
BCRX

Segment breakdown not available.

Related Comparisons